Please Click the Issue to Download
Introduction
Graft-versus-host disease (GVHD) is a formidable systemic complication post allo-HSCT that can result in mortality and significant morbidity. In this exclusive Journal of Hematology Oncology Pharmacy publication, Katie Gatwood, PharmD, BCOP, and Amir Ali, PharmD, offer a comprehensive exploration of GVHD and the guidelines associated with its management.
Supported through funding by
